CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic landscape of lymphoma. After the tumor antigens are identified by scFv, ...

(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 ...

Cancer plasticity allows tumor cells to change their identity, evade therapies, and adapt to environmental pressures, contributing to treatment resistance and metastasis. New research is targeting ...

Hyperthermia, a cancer treatment using controlled heat to kill tumor cells, shows promise but faces limitations due to some ...

New U.S. investor The Institute for Follicular Lymphoma Innovation (IFLI), a global non-profit foundation dedicated to advancing research and treatment for follicular lymphoma, invested $9 million in ...

Pheast Therapeutics, a clinical-stage biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the U.S. Food ...

Immune escape plays an important role in tumor recurrence, metastasis, and drug resistance. Tumors evade immune response through various mechanisms, among which cancer immunoediting is widely accepted ...

Immune escape is a key mechanism of cancer progression and metastatic dissemination and creates a serious obstacle to successful cancer treatment. It has been widely recognized, indeed, that cancerous ...